12:00 AM
 | 
Sep 27, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gilenya fingolimod regulatory update

FDA approved Gilenya fingolimod from Novartis to treat relapsing forms of multiple sclerosis (MS). The approval includes a REMS on the safe use and possible risks of Gilenya, which include slow heart rate, infections, macular edema and...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >